IMTX Stock Analysis: Buy, Sell, or Hold?
IMTX - Immatics N.V. Ordinary Shares
$9.30
-0.07 (-0.75%)
▼
5d:
-2.21%
30d:
-10.06%
90d:
-9.0%
BUY
MODERATE Confidence
Analysis Updated: Mar 30, 2026 12:00 AM ET
Earnings: May 12, 2026
Get Alerted When IMTX Hits Your Target Price
Join 10,000+ traders who never miss a move
You're in! Check your email to confirm and set your target price.
100% Free
No spam, ever
Unsubscribe anytime
Interactive Price Chart (1 Month)
Loading chart...
Loading historical data...
Bottom Line:
💡 BUY OPPORTUNITY: IMTX shows positive signals but monitor for confirmation. Company currently unprofitable (negative forward earnings). Moderate conviction.
💡 BUY OPPORTUNITY: IMTX shows positive signals but monitor for confirmation. Company currently unprofitable (negative forward earnings). Moderate conviction.
In-depth Analysis How we analyze
Valuation Analysis: IMTX is currently trading at $9.30, which is considered oversold relative to its 30-day fair value range of $9.50 to $10.20.
Technical Outlook: Technically, IMTX is showing sideways momentum. The price is currently testing key support at $9.13. A bounce from this level would confirm strength, while a break below could signal further downside.
Market Sentiment: IMTX has a weak technical setup (25/100), with bearish trendlines and momentum suggesting caution for short-term entries. Wall Street analysts see significant upside, with an average price target of $18.75 (+100.1%). Combining these factors, the current setup offers a favorable risk/reward ratio for buyers.
Technical Outlook: Technically, IMTX is showing sideways momentum. The price is currently testing key support at $9.13. A bounce from this level would confirm strength, while a break below could signal further downside.
Market Sentiment: IMTX has a weak technical setup (25/100), with bearish trendlines and momentum suggesting caution for short-term entries. Wall Street analysts see significant upside, with an average price target of $18.75 (+100.1%). Combining these factors, the current setup offers a favorable risk/reward ratio for buyers.
Quick Decision Summary
Current Position
OVERSOLD
Fair Price Range
$9.50 -
$10.20
Company Quality Score
53/100
(HOLD)
Options IV Signal
50th percentile
(NORMAL)
Volume Confirmation
HIGH
Confidence Score
60.4%
All Signals
- BULLISH: Price oversold vs 30-day range
- NEUTRAL: Options fairly priced (IV 50th percentile)
- BEARISH: Weak technical setup (25/100)
- BULLISH: High volume confirmation
- BULLISH: Trading 100.1% below Wall St target ($18.75)
Fair Price Analysis
30-Day Fair Range
$9.50 -
$10.20
Current vs Fair Value
OVERSOLD
Expected Move (7 Days)
±$1.04
(11.2%)
Support & Resistance Levels
Support Level
$9.13
Resistance Level
$10.03
Current Trend
Sideways
Technical data as of
Mar 30, 2026
Fundamental Context
Forward P/E (Next Year Est.)
-5.31
Wall Street Target
$18.75
(+100.1%)
Revenue Growth (YoY)
-64.9%
Share & Embed Analysis
Last updated: March 30, 2026 4:29 PM ET
Data refreshes hourly during market hours. Next update: 5:29 PM
Data refreshes hourly during market hours. Next update: 5:29 PM
🔥 Top Stocks Breaking Out Now
| Ticker | Score | Recommendation | Change % |
|---|
Technical Signals Check
Is IMTX showing a specific setup today?
Insider Activity (6 Months)
0
Buys
0
Sells
0
Net
NEUTRAL
Top Rated Biotechnology Stocks
Top-rated stocks in Biotechnology by analyst ratings.
| Stock | Analyst Consensus | Analyst Target | Tradestie Score |
|---|---|---|---|
|
AXSM
Axsome Therapeutics Inc |
STRONG BUY
19 analysts |
$222 | 59 HOLD |
|
CYTK
Cytokinetics Inc |
STRONG BUY
21 analysts |
$92 | 62 BUY |
|
RARE
Ultragenyx |
STRONG BUY
20 analysts |
$54 | 53 HOLD |
|
INCY
Incyte Corporation |
HOLD
27 analysts |
$108 | 61 BUY |
|
RVMD
Revolution Medicines Inc |
STRONG BUY
12 analysts |
$134 | 59 HOLD |
